Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HELP Committee Leaders Add Voice To Doubts About New User Fees

This article was originally published in The Tan Sheet

Executive Summary

HELP Chairman Harkin and ranking member Enzi say potential riders added to the FDA user fee bill could slow down passage and add more work for agency staff. The senators’ concern follows House appropriators’ doubts as obstacles to approval for new food safety user fees.

You may also be interested in...



FDA Budget Proposal Shifts More Toward User Fees Reliance

User fees make up the bulk of FDA’s human drug spending under President Obama’s fiscal 2014 budget proposal, a trend fueled by new user fee programs and cuts to taxpayer funding.

FDA Budget Proposal Shifts More Toward User Fees Reliance

User fees make up the bulk of FDA’s human drug spending under President Obama’s fiscal 2014 budget proposal, a trend fueled by new user fee programs and cuts to taxpayer funding.

New Food And Drug User Fees Face Long Odds In Congress

FDA’s $4.7 billion fiscal 2014 budget request proposes new fees including $58.9 million from food establishment registrations and inspections, $19.1 million from cosmetics firms and $15.04 million from medical product reinspections.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel